All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia (CLL). Professor Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, discusses treatment options for a patient with ibrutinib-resistant CLL.
Treatment options for a patient with ibrutinib-resistant CLL
Bosch presents his treatment approach to a double-refractory ibrutinib-resistant patient case by firstly discussing the significance of predictive markers and how to use these to discern between different treatments. He then moves on to outline the therapeutic options for this case, including alternative BTK inhibitors, PI3 kinase inhibitors, and CAR T-cell therapy.
Satellite Symposium | Treatment options for a patient with ibrutinib-resistant CLL
If you would like to download the slides from Francesc Bosch's presentation, click belowDownload here
ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Did you miss ASH 2018? The Lymphoma Hub has developed a downloadable resource, which provides information on the practice changing abstracts across...
Dr Francesc Bosch | ASH 2017 | Do you believe checkpoint inhibitors will become the standard of care in CLL?
59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Dr Francesc Bosch Interview topic: Do you believe that checkpoint...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox